Navigation Links
BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial
Date:7/17/2008

us (grade 3 and 4) treatment related adverse events. A substantial reduction in chemotherapy-induced renal (kidney) toxicity and nausea/vomiting was also observed in the Tavocept group.

"The observations from the U.S. Tavocept Trial are extremely encouraging," said Frederick H. Hausheer, M.D., chairman & chief executive officer of BioNumerik. "The increase in patient survival with Tavocept compares favorably to observations seen for other cancer drugs. For example, the cancer drug Avastin(R) (also known as bevacizumab) was approved in the United States to treat lung cancer while exhibiting a survival increase of approximately two months when used with a standard chemotherapy treatment regimen. Recent data for the cancer drug Erbitux(R) (also known as cetuximab) demonstrated a survival increase of about 1.2 months compared to chemotherapy alone in patients with advanced epidermal growth-factor receptor (EGFR)- detectable non-small-cell lung cancer."

Earlier this year, BioNumerik and ASKA Pharmaceutical Co., Ltd. ("ASKA") reported results from a randomized, multi-center Phase III clinical trial of Tavocept that also indicated a survival increase in adenocarcinoma and non- small cell lung cancer patients. That clinical trial (the "Japan Tavocept Trial") was conducted in Japan by ASKA and involved 182 advanced non-small cell lung cancer patients who received the chemotherapy drugs paclitaxel and cisplatin every three weeks. Half of the patients in the trial received Tavocept along with their chemotherapy, while the other half received a placebo and chemotherapy. The results from the Japan Tavocept Trial demonstrated an observed increase in median survival time of approximately 138 days (4.5 months) for adenocarcinoma patients receiving Tavocept as compared to those receiving placebo. For all non-small cell lung cancer patients participating in the Japan Tavocept Trial, the median survival time observed for patients receiving Tavocept was approximately 40 d
'/>"/>

SOURCE BioNumerik Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
2. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
3. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
4. MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion
5. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
6. MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
7. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial
8. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
9. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
10. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
11. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... April 20, 2015 Research published today in ... Sciences (PNAS) demonstrates that technology invented by ... Casey Eye Institute can improve the clinical ... coherence tomography (OCT) angiography could largely replace current ... OHSU researchers found that OCT angiography ...
(Date:4/20/2015)... Mass. , April 20, 2015 ... and final clinical results for the Phase 1 ... in HER2-positive metastatic breast cancer.  The results were ... clinical trials plenary oral session at the 2015 ... in Philadelphia, PA. Data ...
(Date:4/20/2015)... YORK , April 20, 2015 This report ... Instruments in US$ Million by the following Product Segments: Sphygmomanometers ... and Blood Pressure Transducers. The report provides separate comprehensive analytics ... Japan , Europe , ... Latin America . Annual estimates and forecasts ...
Breaking Medicine Technology:Study shows new technology may improve management of leading causes of blindness 2Study shows new technology may improve management of leading causes of blindness 3Study shows new technology may improve management of leading causes of blindness 4Study shows new technology may improve management of leading causes of blindness 5Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 2Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 3Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 4Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 5World Blood Pressure Monitoring and Measurement Instruments Industry 2World Blood Pressure Monitoring and Measurement Instruments Industry 3World Blood Pressure Monitoring and Measurement Instruments Industry 4World Blood Pressure Monitoring and Measurement Instruments Industry 5World Blood Pressure Monitoring and Measurement Instruments Industry 6World Blood Pressure Monitoring and Measurement Instruments Industry 7World Blood Pressure Monitoring and Measurement Instruments Industry 8World Blood Pressure Monitoring and Measurement Instruments Industry 9World Blood Pressure Monitoring and Measurement Instruments Industry 10World Blood Pressure Monitoring and Measurement Instruments Industry 11World Blood Pressure Monitoring and Measurement Instruments Industry 12World Blood Pressure Monitoring and Measurement Instruments Industry 13World Blood Pressure Monitoring and Measurement Instruments Industry 14World Blood Pressure Monitoring and Measurement Instruments Industry 15World Blood Pressure Monitoring and Measurement Instruments Industry 16World Blood Pressure Monitoring and Measurement Instruments Industry 17World Blood Pressure Monitoring and Measurement Instruments Industry 18World Blood Pressure Monitoring and Measurement Instruments Industry 19World Blood Pressure Monitoring and Measurement Instruments Industry 20World Blood Pressure Monitoring and Measurement Instruments Industry 21World Blood Pressure Monitoring and Measurement Instruments Industry 22World Blood Pressure Monitoring and Measurement Instruments Industry 23World Blood Pressure Monitoring and Measurement Instruments Industry 24World Blood Pressure Monitoring and Measurement Instruments Industry 25World Blood Pressure Monitoring and Measurement Instruments Industry 26World Blood Pressure Monitoring and Measurement Instruments Industry 27World Blood Pressure Monitoring and Measurement Instruments Industry 28
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today ... 2010.  Third quarter 2010 net revenues were $42.0 million, ... 2009.  Excluding the recognition of one-time license revenue in ... 44%.  Net loss for the third quarter ended September ...
... 2, 2010 Cannabis Science, Inc. (OTC Bulletin Board: ... cannabis products, is pleased to announce to its shareholders and ... decisions and processes regarding the new class of common shares. ... 1 for 10 new share dividend payment for shareholders of ...
Cached Medicine Technology:ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 2ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 3ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 4ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 5ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 6ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 7ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 8ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 9ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 10Cannabis Science Announces a Proposed 10:1 Ratio Structured Dividend Payout for a New Class of Common Shares to Shareholders of Record as of November 30, 2010 2Cannabis Science Announces a Proposed 10:1 Ratio Structured Dividend Payout for a New Class of Common Shares to Shareholders of Record as of November 30, 2010 3
(Date:4/20/2015)... 20, 2015 Mutare Health, a ... nationally-renowned Gastroenterologist Lawrence Kosinski, MD, MBA, AGAF, to ... Kosinski brings a unique combination of medical experience, ... Mutare Health team as it continues ... and quality of care in the healthcare environment. ...
(Date:4/20/2015)... 20, 2015 Novatus, a leading ... expanded its service level to the growing European ... Amsterdam and Paris. After a rigorous review ... levels of resilience, security and operational expertise, and ... for Novatus as we expand our footprint and ...
(Date:4/20/2015)... York (PRWEB) April 20, 2015 ... representing the U.S. health insurance industry, is seeking ... of the recent controversy involving surgical tools called ... to U.S. Senator Robert Casey (D-PA) dated April ... surrounding uterine morcellation point to “serious gaps in ...
(Date:4/20/2015)... 1% for the Planet , one of ... Kate Williams, the network’s Director of Partnerships, will step into ... has been part of 1% for the Planet since early ... the Northern Forest Canoe Trail, a 1% for the Planet ... stewardship of and advocacy for the outdoors, a commitment which ...
(Date:4/20/2015)... Grateful Dead originally formed in 1965 in ... The group was more than just about rock music. They ... rock, country, and other genres to put together their greatest ... group was inducted into the Rock and Roll Hall of ... 35 million records worldwide. This year marks the 50th ...
Breaking Medicine News(10 mins):Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 2Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 3Health News:Novatus Expands into European Data Centers 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 4Health News:1% for the Planet Announces New CEO 2Health News:1% for the Planet Announces New CEO 3Health News:Grateful Dead Tickets at Levi’s Stadium in Santa Clara: Ticket Down Slashes Grateful Dead Tickets in Santa Clara @ Levi’s Stadium for "Fare Thee Well" 50th Anniversary 2
... an AIDS drug and a heart medicine, and entered into ... more people can be treated. ,The negotiation panel ... first talks with US firm Abbott to discuss a price ... head of the department of disease control, said the firm ...
... the light-sensitive protein found in many marine bacteria. ... National Laboratory (Berkeley Lab) and the University of California ... respire oxygen is impaired, bacterium equipped with proteorhodopsin will ... processes. ,“Our research shows that proteorhodopsin ...
... accurately identify colorectal cancer patients with a specific type ... patient has an inherited// form of the disease or ... ,Some people with colorectal cancer have defects in ... these mutations by looking for a gene marker called ...
... solved a decades-old cancer mystery. "We not only found ... master switch for a tumor suppressive network that means ... said CSHL Associate Professor Alea Mills, Ph.D. The study, ... of Cell. ,Specifically, Mills' discovery identifies CHD5, ...
... cases of malaria due to Plasmodium falciparum on the island ... reported cases, 264 have occurred in Kingston// , 12 in ... There have been no reported deaths due to malaria. ... the WHO Regional Office for the Americas coordinated by the ...
... IV study of KADIAN ? (morphine sulfate extended-release) Capsules ... leading pharmaceutical company. It reveals that the pharmacokinetics// of ... consumption of alcohol. ,Results of this pharmacokinetic ... by the U.S. Food and Drug Administration (FDA) to ...
Cached Medicine News:Health News:Thailand Backs Off Threat to Break Drug Patents 2Health News:Shedding New Light on Proteorhodopsin 2Health News:Scientists Discover New Gene 2Health News:KADIAN Efficacy Not Affected by Alcohol Consumption 2
Bio-Rad's Liquichek™ D-dimer Control provides the laboratory with a liquid, trilevel, human plasma based control for the monitoring of D-dimer testing on most automated coagulation, chemistry a...
Lyphochek Coagulation Control is a human plasma control for monitoring the performance of routine coagulation tests. It has an extended reconstituted stability which helps reduce waste and save money...
Lyphochek Diabetes Control is a human whole blood based product used to monitor hemoglobin fractions associated with diabetes, including Hemoglobins A1, A1C, F and Total Glycated Hemoglobin....
... Liquichek Qualitative Urine Toxicology Control is a ... rapid urine drug screen panels, including Point ... test kits like Bio-Rad TOX/See, Biosite Triage ... qualitative results (+/) for popular kits and ...
Medicine Products: